SCHEMBL1346853

SCHEMBL1346853

CCCN1CCc2cc(F)cc3c2[C@H]1Cc1cccc(O)c1-3

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 7/20 0.78
DRD3 P35462 5/20 0.78
DRD1 P21728 5/20 0.78
TH P07101 4/20 0.78
HTR1A P08908 2/20 0.78
HTR2A P28223 1/20 0.78
MAPT P10636 3/20 0.64
MAPK1 P28482 3/20 0.64
KDM4E B2RXH2 2/20 0.64
GMNN O75496 2/20 0.64
LMNA P02545 2/20 0.64
HPGD P15428 2/20 0.64
GFER P55789 2/20 0.64
PMP22 Q01453 2/20 0.64
KMT2A Q03164 2/20 0.64
SMN1; SMN2 Q16637 2/20 0.64
TDP1 Q9NUW8 2/20 0.64
RGS12 O14924 2/20 0.64
TP53 P04637 2/20 0.64
CYP1A2 P05177 2/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1345828 1.00 DRD2 (0.78) DRD2DRD3DRD1THHTR1A
SCHEMBL12877963 0.88 DRD1 (0.79) DRD2DRD3DRD1THHTR1A
SCHEMBL1203699 0.88 DRD2 (1.00) DRD2DRD3DRD1THHTR1A
SCHEMBL10754712 0.88 DRD2 (1.00) DRD2DRD3DRD1THHTR1A
SCHEMBL1203698 0.88 DRD2 (1.00) DRD2DRD3DRD1THHTR1A
SCHEMBL12284387 0.87 DRD3 (1.00) DRD2DRD3DRD1THMAPT
SCHEMBL14535819 0.87 DRD3 (1.00) DRD2DRD3DRD1THMAPT
SCHEMBL1347782 0.86 DRD2 (0.75) DRD2DRD3DRD1THHTR1A
SCHEMBL1346072 0.86 DRD2 (0.75) DRD2DRD3DRD1THHTR1A
Hydrochloric Acid SCHEMBL10752801 0.86 DRD2 (0.98) DRD2DRD3DRD1THHTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063060-B2 R(−)-11-hydroxyaporphine derivatives and uses thereof THE MCLEAN HOSPITAL CORPORATION (US) 2011-11-22 US disclosed
US-20100081651-A1 R(-)-11-HYDROXYAPORPHINE DERIVATIVES AND USES THEREOF THE MCLEAN HOSPITAL CORPORATION (US) 2010-04-01 US disclosed
US-7648995-B2 R(—)-11-hydroxyaporphine derivatives and uses thereof THE MCLEAN HOSPITAL CORPORATION (US) 2010-01-19 US disclosed
US-20060040900-A1 R(-)-11-hydroxyaporphine derivatives and uses thereof MCLEAN HOSPITAL CORPORATION, THE 2006-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060040900-A1 R(-)-11-hydroxyaporphine derivatives and uses thereof SNCA, HTR5A, PARK7 DRD2 23/4885DRD3 45/4885DRD1 34/4885
US-20100081651-A1 R(-)-11-HYDROXYAPORPHINE DERIVATIVES AND USES THEREOF SNCA, HTR5A, HTR3A DRD2 23/4885DRD3 50/4885DRD1 36/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.